Prurigo nodularis Archives

Regeneron, Sanofi Blockbuster Dupixent Scores Points in 5 More Indications

Asthma, Atopic Dermatitis (Eczema), Blockbusters, Chronic Idiopathic Urticaria, Chronic rhinosinusitis with nasal polyps (CRSwNP), Clinical Trials, ENT Diseases, Eosinophilic Esophagitis, Human Antibodies, Immunosuppressants, Prurigo nodularis, R&D, Regeneron Pharmaceuticals, Rhinosinusitis, Sanofi, Therapeutics

Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.

February 2, 2022/by BioSpace

Regeneron, Sanofi on a Roll as Dupixent Scores Second Consecutive Phase III Win

Blockbusters, Clinical Trial Endpoints, Clinical Trials, Eosinophilic Esophagitis, Inflammatory Diseases, Primary Endpoints, Prurigo nodularis, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics

Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).

October 25, 2021/by Andrew Humphreys